Sirnaomics Ltd. announced that Dr. Xiaochang Dai ("Dr. Dai") has been appointed as the Chief Strategy Officer of the Group, re-designated from the position of Scientific and Strategic Director by the Board with effect from August 30, 2023, due to changes in his functions and responsibilities within the Group. Dr. Dai, aged 60, is an executive Director and the Chief Strategy Officer of the Group. Dr. Dai participates in the formulation of the general corporate business plans, strategies and major decisions of the Company through the Board.

Dr. Dai is a member of the remuneration committee of the Board (the "Remuneration Committee"). He is also a director of certain subsidiaries of the Company. Dr. Dai currently serves as a professor at School of Chemical Science and Engineering, Yunnan University since 2000, the executive director of Value Measure Investments Limited since January 2011 and the executive director of Trinity Power Limited since March 2012, respectively.

Dr. Dai also serves as a director of Shenzhen Yunda Technology Industry Co. Ltd. since August 2001. Prior to joining the Group, Dr. Dai served as the executive director, director of scientific advisory committee, director of postdoctoral workstation, chief scientist at Yunda Technology Co.

Ltd., a company used to be listed on Shanghai Stock Exchange (stock code: 600181) and delisted since June 1, 2007, from January 2000 to December 2001, the chairman and general manager of Dalian High-tech Biopharmaceutical Co. Ltd. in 2001, the chairman of Yunnan Walvax Biopharmaceutical Co. Ltd., the predecessor of Walvax Biotechnology Co.

Ltd., a company listed on Shenzhen Stock Exchange (stock code: 300142) from 2002 to 2004, the managing director of Kunming Baker Norton Pharmaceutical Co. Ltd. in 2005, and the president of Kunyao Group Co. Ltd., a company listed on Shanghai Stock Exchange (stock code: 600422), from September 2015 to December 2017.

Dr. Dai obtained a bachelor's degree in chemistry in School of Chemistry, Yunnan Normal University in the PRC in July 1983, a master's degree in biochemistry in Shanghai Institute of Biochemistry, Chinese Academy of Sciences in the PRC in July 1988, and a doctoral degree in chemistry from The Scripps Research Institute in San Diego, California, U.S. in September 1998, respectively. He also conducted postdoctoral research in the laboratory of John N. Ablelson, Division of Biology and Biological Engineering, California Institute of Technology in the U.S. from November 1998 to December 1999. The Board considered and accepted the recommendation from the nomination committee of the Board to the appointment of Dr. Dai as Chief Strategy Officer, after reviewing his academic qualifications, working experience and contributions to the Group.

As at the date of this announcement, Dr. Dai was deemed to be interested in an aggregate of 8,545,007 shares of the Company (the "Shares") and underlying Shares, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Dr. Dai is entitled to an annual emolument of USD 277,650 which is determined by the Board with reference to his background, qualifications, experience, level of responsibilities undertaken with the Group and prevailing market conditions. The emolument of Dr. Dai will be subject to annual review by the Remuneration Committee and the Board.

The Board hereby announces that the Board has received a letter of resignation from Ms. Yun Zhang (alias Monica Zhang) ("Ms. Zhang") to resign as a joint company secretary of the Company with effect from August 31, 2023. Ms. Zhang has confirmed that she had no disagreement with the Board and there were no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company or the Hong Kong Stock Exchange. Following the resignation of Ms. Zhang, the other joint company secretary of the Company, Mr. Leung Ting Cheung, who possesses the qualifications and experience of company secretary as required under Rule 3.28 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange, will remain in office and act as the sole company secretary of the Company.